Myeloproliferative neoplasms in the young: Mayo Clinic experience with 361 patients age 40 years or younger

Natasha Szuber, Rangit R. Vallapureddy, Domenico Penna, Terra L. Lasho, Christy Finke, Curtis A Hanson, Rhett Patrick Ketterling, Animesh Pardanani, Naseema Gangat, Ayalew Tefferi

Research output: Contribution to journalArticlepeer-review

18 Scopus citations

Abstract

Between 1967 and 2017, 361 patients with myeloproliferative neoplasms (MPN), age ≤ 40 years, were seen at our institution, constituting 12% of all MPN patients (n = 3023) seen during the same time period; disease-specific incidences were 12% in polycythemia vera (PV; n = 79), 20% in essential thrombocythemia (ET; n = 219) and 5% in primary myelofibrosis (PMF; n = 63). Compared to their older counterparts, younger patients were more likely to present with low risk disease (P <.001) and display female preponderance in ET (P =.04), lower incidence of arterial events overall (P <.001), and higher incidence of venous thrombosis in PV (P =.01). Younger patients were also more likely to express CALR mutations, in ET and PMF, normal karyotype, in PV and PMF, and lower incidence of high molecular risk mutations in PMF (P significant in all instances). Over median follow-up of 11.3, 13, and 7.1 years for PV, ET, and PMF, leukemic transformations were respectively documented in 4%, 2%, and 10% (P values 0.1-0.9) while incidences of fibrotic progression in PV (22%) and ET (16%) were expectedly higher in young patients, because of their longer survival (P <.001). Median survival in young patients was 37 years for PV, 35 for ET and 20 for PMF; the corresponding values were 22, 22, and 8 years for ages 41-60 years and 10, 11, and 3 years for ages >60 years (P <.001). Young MPN patients comprise a unique disease subset defined by an attenuated-risk cytogenetic and mutational backdrop and conspicuously longer survival compared to their older counterparts, which requires assertion during patient counseling.

Original languageEnglish (US)
JournalAmerican Journal of Hematology
DOIs
StateAccepted/In press - Jan 1 2018

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'Myeloproliferative neoplasms in the young: Mayo Clinic experience with 361 patients age 40 years or younger'. Together they form a unique fingerprint.

Cite this